Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Feb 13  •  04:00PM ET
100.82
Dollar change
-0.51
Percentage change
-0.50
%
IndexRUT P/E- EPS (ttm)-5.32 Insider Own34.39% Shs Outstand66.84M Perf Week-2.67%
Market Cap7.33B Forward P/E- EPS next Y-5.76 Insider Trans-4.64% Shs Float47.70M Perf Month-6.51%
Enterprise Value6.39B PEG- EPS next Q-1.48 Inst Own82.10% Short Float12.19% Perf Quarter3.91%
Income-381.44M P/S- EPS this Y-45.44% Inst Trans6.99% Short Ratio9.37 Perf Half Y31.28%
Sales0.00M P/B8.62 EPS next Y-0.84% ROA-35.18% Short Interest5.81M Perf YTD0.23%
Book/sh11.70 P/C7.77 EPS next 5Y-2.52% ROE-38.79% 52W High113.01 -10.79% Perf Year24.55%
Cash/sh12.97 P/FCF- EPS past 3/5Y-59.96% -74.22% ROIC-45.12% 52W Low55.53 81.54% Perf 3Y220.47%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility5.17% 4.66% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM-52.84% Oper. Margin- ATR (14)4.91 Perf 10Y-
Dividend Ex-Date- Quick Ratio10.73 Sales Y/Y TTM- Profit Margin- RSI (14)45.11 Recom1.17
Dividend Gr. 3/5Y- - Current Ratio10.73 EPS Q/Q-32.15% SMA20-3.41% Beta1.33 Target Price142.65
Payout- Debt/Eq0.00 Sales Q/Q- SMA50-3.10% Rel Volume0.67 Prev Close101.33
Employees142 LT Debt/Eq0.00 EarningsOct 30 BMO SMA20014.34% Avg Volume620.14K Price100.82
IPOJul 29, 2021 Option/ShortYes / Yes EPS/Sales Surpr.-22.52% - Trades Volume414,839 Change-0.50%
Date Action Analyst Rating Change Price Target Change
Nov-24-25Initiated Truist Buy
Nov-12-25Initiated Canaccord Genuity Buy $126
Oct-16-25Resumed Stifel Buy $115
Oct-15-25Initiated Cantor Fitzgerald Overweight $135
Sep-04-25Resumed Guggenheim Buy $122
Sep-03-25Initiated Raymond James Outperform $105
Aug-19-25Initiated Piper Sandler Overweight $112
Mar-14-25Upgrade UBS Neutral → Buy $100
Dec-30-24Initiated H.C. Wainwright Buy $110
Oct-24-24Initiated UBS Neutral $100
Feb-14-26 12:03PM
Feb-05-26 06:30AM
Jan-20-26 10:42AM
Jan-12-26 06:30AM
Dec-29-25 09:13AM
06:30AM Loading…
Dec-22-25 06:30AM
Dec-10-25 04:01PM
Dec-09-25 12:20AM
Nov-26-25 06:30AM
Nov-24-25 04:01PM
Nov-19-25 04:19PM
Nov-18-25 11:50PM
06:24AM
Nov-17-25 04:40PM
04:01PM
06:32AM Loading…
06:32AM
06:30AM
Nov-14-25 04:01PM
Nov-12-25 09:45AM
Nov-04-25 05:12PM
Oct-30-25 06:30AM
Oct-18-25 06:00AM
Oct-13-25 12:53PM
Sep-24-25 06:30AM
Sep-07-25 04:45AM
Sep-02-25 01:34AM
Aug-28-25 06:30AM
Aug-13-25 01:06PM
Aug-07-25 06:30AM
Jul-21-25 06:30AM
06:30AM Loading…
06:30AM
Jul-06-25 04:00AM
Jun-25-25 10:20AM
10:15AM
Jun-24-25 06:30AM
06:30AM
Jun-23-25 04:30PM
Jun-18-25 04:30PM
May-08-25 07:31AM
Apr-29-25 01:09PM
Apr-23-25 08:48PM
12:47PM
10:28AM
Apr-08-25 04:00PM
Apr-01-25 08:25AM
06:30AM
Mar-25-25 05:24PM
Mar-20-25 09:05AM
Feb-28-25 06:30AM
Feb-27-25 06:30AM
Feb-11-25 01:47PM
Jan-20-25 03:07PM
Jan-13-25 06:30AM
Dec-30-24 09:43AM
Dec-19-24 06:30AM
Dec-09-24 06:30AM
Nov-26-24 06:52AM
Nov-12-24 06:30AM
Sep-18-24 04:05PM
Sep-16-24 10:23PM
04:04PM
11:18AM
07:00AM
Sep-14-24 07:57PM
05:29PM
05:00AM
Sep-13-24 09:53AM
Sep-09-24 06:30AM
Aug-29-24 06:30AM
Aug-08-24 06:30AM
Jul-23-24 04:52AM
Jul-22-24 06:30AM
Jul-16-24 06:30AM
Jul-11-24 06:30AM
Jun-24-24 06:00AM
May-29-24 06:30AM
May-17-24 04:48PM
06:31AM
May-16-24 04:23PM
04:01PM
May-09-24 01:56PM
09:27AM
07:19AM
06:30AM
May-08-24 05:22PM
10:21AM
May-01-24 05:05PM
Apr-08-24 04:30PM
Apr-05-24 07:00PM
06:30PM
Mar-29-24 07:01PM
Mar-25-24 07:01PM
Mar-19-24 07:01PM
Mar-05-24 04:52PM
Feb-29-24 04:32AM
Feb-27-24 06:30AM
06:15AM
Feb-22-24 04:00AM
Feb-12-24 06:30AM
Feb-01-24 06:30AM
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Noci DarleneChief Development OfficerJan 29 '26Option Exercise27.855,500153,17563,617Feb 02 04:30 PM
Noci DarleneChief Development OfficerJan 29 '26Sale102.085,500561,42258,117Feb 02 04:30 PM
Miller Deborah AnnChief Legal OfficerJan 22 '26Option Exercise27.8514,300398,25573,934Jan 23 04:31 PM
Miller Deborah AnnChief Legal OfficerJan 21 '26Option Exercise27.8570019,49560,334Jan 23 04:31 PM
Miller Deborah AnnChief Legal OfficerJan 22 '26Sale110.1614,3001,575,28859,634Jan 23 04:31 PM
Miller Deborah AnnChief Legal OfficerJan 21 '26Sale109.8470076,88859,634Jan 23 04:31 PM
DEBORAH MILLER OfficerJan 22 '26Proposed Sale109.0421,0002,289,840Jan 22 04:33 PM
Pelish Henry E.Chief Scientific OfficerJan 06 '26Sale97.172,664258,84865,888Jan 07 05:27 PM
Pelish Henry E.Chief Scientific OfficerJan 05 '26Sale97.322,496242,90568,552Jan 07 05:27 PM
Noci DarleneChief Development OfficerJan 05 '26Sale97.324,236412,23943,798Jan 07 05:26 PM
Noci DarleneChief Development OfficerJan 06 '26Sale97.163,181309,08140,617Jan 07 05:26 PM
Miller Deborah AnnChief Legal OfficerJan 05 '26Sale97.324,363424,59844,723Jan 07 05:26 PM
Miller Deborah AnnChief Legal OfficerJan 06 '26Sale97.162,589251,56042,134Jan 07 05:26 PM
Turner Christopher DurantChief Medical OfficerJan 05 '26Sale97.324,236412,23958,311Jan 07 05:26 PM
Turner Christopher DurantChief Medical OfficerJan 06 '26Sale97.163,181309,08155,130Jan 07 05:26 PM
Balcom AlexandraChief Financial OfficerJan 05 '26Sale97.324,236412,23984,914Jan 07 05:25 PM
Balcom AlexandraChief Financial OfficerJan 06 '26Sale97.163,181309,08181,733Jan 07 05:25 PM
Porter James RichardPresident and CEOJan 05 '26Sale97.3217,8901,741,016288,172Jan 07 05:25 PM
Porter James RichardPresident and CEOJan 06 '26Sale97.169,543927,244278,629Jan 07 05:25 PM
Henry E. PelishOfficerJan 05 '26Proposed Sale97.322,496242,901Jan 05 08:58 PM
Darlene NociOfficerJan 05 '26Proposed Sale97.324,236412,232Jan 05 08:58 PM
Deborah Ann MillerOfficerJan 05 '26Proposed Sale97.324,363424,591Jan 05 08:57 PM
Christopher Durant TurnerOfficerJan 05 '26Proposed Sale97.324,236412,232Jan 05 08:55 PM
Alexandra BalcomOfficerJan 05 '26Proposed Sale97.324,236412,232Jan 05 08:54 PM
James Richard PorterOfficerJan 05 '26Proposed Sale97.3217,8901,740,989Jan 05 08:53 PM
Noci DarleneChief Development OfficerDec 30 '25Option Exercise27.854,000111,40052,034Jan 02 04:20 PM
Noci DarleneChief Development OfficerDec 30 '25Sale100.044,000400,17948,034Jan 02 04:20 PM
Darlene NociOfficerDec 30 '25Proposed Sale101.6015,0001,524,000Dec 30 04:03 PM
Pelish Henry E.Chief Scientific OfficerDec 22 '25Option Exercise1.085,0855,49271,048Dec 23 04:31 PM
Balcom AlexandraChief Financial OfficerDec 22 '25Option Exercise1.0834,50037,26089,150Dec 23 04:30 PM
Porter James RichardPresident and CEODec 19 '25Option Exercise0.6557,00037,050306,062Dec 23 04:30 PM
Balcom AlexandraChief Financial OfficerDec 08 '25Sale110.327,084781,53754,650Dec 10 04:30 PM
Alexandra BalcomOfficerDec 08 '25Proposed Sale109.607,084776,406Dec 08 08:36 PM
Noci DarleneChief Development OfficerNov 28 '25Option Exercise27.854,000111,40052,034Dec 02 04:30 PM
Noci DarleneChief Development OfficerNov 28 '25Sale108.584,000434,31948,034Dec 02 04:30 PM
Shair MatthewDirectorNov 24 '25Sale109.375,850639,8141,377,194Nov 26 04:30 PM
Shair MatthewDirectorNov 24 '25Sale109.371,650180,460201,672Nov 26 04:30 PM
Flynn James EDirector by DeputizationNov 24 '25Sale95.44742,57470,874,9758,299,225Nov 24 08:00 PM
Balcom AlexandraChief Financial OfficerNov 17 '25Option Exercise49.8520,000996,96281,734Nov 19 05:14 PM
Balcom AlexandraChief Financial OfficerNov 18 '25Option Exercise72.3572952,74362,463Nov 19 05:14 PM
Balcom AlexandraChief Financial OfficerNov 17 '25Sale99.4520,0001,989,02561,734Nov 19 05:14 PM
Balcom AlexandraChief Financial OfficerNov 18 '25Sale104.2672976,00561,734Nov 19 05:14 PM
Miller Deborah AnnChief Legal OfficerNov 17 '25Option Exercise6.8924,200166,73873,286Nov 19 05:13 PM
Miller Deborah AnnChief Legal OfficerNov 17 '25Sale105.5024,2002,552,99949,086Nov 19 05:13 PM
DEBORAH MILLER OfficerNov 17 '25Proposed Sale96.5017,2001,659,800Nov 17 04:37 PM
Alexandra BalcomOfficerNov 17 '25Proposed Sale93.7213,8541,298,397Nov 17 04:09 PM
Noci DarleneChief Development OfficerOct 30 '25Option Exercise27.854,000111,40052,034Oct 31 04:31 PM
Noci DarleneChief Development OfficerOct 30 '25Sale102.924,000411,66148,034Oct 31 04:31 PM
Miller Deborah AnnChief Legal OfficerOct 30 '25Option Exercise6.8921,800150,20270,886Oct 31 04:30 PM
Miller Deborah AnnChief Legal OfficerOct 30 '25Sale103.1621,8002,248,94349,086Oct 31 04:30 PM
DEBORAH MILLER OfficerOct 30 '25Proposed Sale102.9722,8002,347,716Oct 30 04:16 PM
Shair MatthewDirectorOct 28 '25Sale100.2732,4553,254,2631,383,044Oct 29 04:31 PM
Shair MatthewDirectorOct 27 '25Sale100.2314,3451,437,7991,415,499Oct 29 04:31 PM
Shair MatthewDirectorOct 28 '25Sale100.279,154917,872203,322Oct 29 04:31 PM
Shair MatthewDirectorOct 27 '25Sale100.234,046405,531212,476Oct 29 04:31 PM
Matthew ShairDirectorOct 27 '25Proposed Sale100.0064,3506,435,000Oct 27 04:09 PM
Matthew ShairDirectorOct 27 '25Proposed Sale100.0018,1501,815,000Oct 27 04:06 PM
Miller Deborah AnnChief Legal OfficerOct 20 '25Option Exercise6.895,00034,45054,086Oct 22 04:32 PM
Miller Deborah AnnChief Legal OfficerOct 20 '25Sale94.915,000474,55049,086Oct 22 04:32 PM
Porter James RichardPresident and CEOOct 16 '25Option Exercise18.9327,000511,110276,062Oct 17 04:32 PM
Porter James RichardPresident and CEOOct 16 '25Sale90.6327,0002,447,021249,062Oct 17 04:32 PM
Miller Deborah AnnChief Legal OfficerOct 15 '25Option Exercise6.8915,624107,64964,710Oct 17 04:32 PM
Miller Deborah AnnChief Legal OfficerOct 16 '25Option Exercise6.8912,37685,27161,462Oct 17 04:32 PM
Miller Deborah AnnChief Legal OfficerOct 15 '25Sale89.9815,6241,405,84849,086Oct 17 04:32 PM
Miller Deborah AnnChief Legal OfficerOct 16 '25Sale91.6612,3761,134,44249,086Oct 17 04:32 PM
Pelish Henry E.Chief Scientific OfficerOct 15 '25Option Exercise35.0814,205498,26080,168Oct 17 04:31 PM
Pelish Henry E.Chief Scientific OfficerOct 15 '25Sale90.0414,2051,279,01865,963Oct 17 04:31 PM
Balcom AlexandraChief Financial OfficerOct 15 '25Option Exercise18.931,68331,85963,417Oct 17 04:31 PM
Balcom AlexandraChief Financial OfficerOct 15 '25Sale85.571,683144,01461,734Oct 17 04:31 PM
James Richard PorterOfficerOct 16 '25Proposed Sale90.0127,0002,430,270Oct 16 04:02 PM
DEBORAH MILLER OfficerOct 15 '25Proposed Sale84.6654,0004,571,640Oct 15 04:37 PM
Balcom AlexandraChief Financial OfficerOct 14 '25Option Exercise18.9320,000378,60081,734Oct 15 04:30 PM
Balcom AlexandraChief Financial OfficerOct 13 '25Option Exercise14.7920,000295,82581,734Oct 15 04:30 PM
Balcom AlexandraChief Financial OfficerOct 13 '25Sale88.5120,0001,770,28861,734Oct 15 04:30 PM
Balcom AlexandraChief Financial OfficerOct 14 '25Sale86.2020,0001,724,01661,734Oct 15 04:30 PM
Pelish Henry E.Chief Scientific OfficerOct 13 '25Option Exercise36.397,637277,90373,600Oct 15 04:30 PM
Pelish Henry E.Chief Scientific OfficerOct 14 '25Option Exercise25.672,43362,46068,396Oct 15 04:30 PM
Pelish Henry E.Chief Scientific OfficerOct 13 '25Sale89.817,637685,87965,963Oct 15 04:30 PM
Pelish Henry E.Chief Scientific OfficerOct 14 '25Sale85.782,433208,69965,963Oct 15 04:30 PM
Alexandra BalcomOfficerOct 13 '25Proposed Sale89.3248,5584,337,206Oct 14 04:08 PM
HENRY E PELISHOfficerOct 13 '25Proposed Sale88.1021,8421,924,280Oct 14 07:43 AM
Balcom AlexandraChief Financial OfficerOct 01 '25Option Exercise8.8220,000176,48581,734Oct 03 04:28 PM
Balcom AlexandraChief Financial OfficerOct 01 '25Sale85.4820,0001,709,51261,734Oct 03 04:28 PM
Balcom AlexandraChief Financial OfficerSep 30 '25Option Exercise6.8920,000137,80081,734Oct 01 08:17 PM
Balcom AlexandraChief Financial OfficerSep 29 '25Option Exercise6.897,58852,28169,322Oct 01 08:17 PM
Balcom AlexandraChief Financial OfficerSep 30 '25Sale85.0620,0001,701,20061,734Oct 01 08:17 PM
Balcom AlexandraChief Financial OfficerSep 29 '25Sale85.017,588645,05661,734Oct 01 08:17 PM
Noci DarleneChief Development OfficerSep 29 '25Option Exercise27.854,000111,40052,034Oct 01 08:14 PM
Noci DarleneChief Development OfficerSep 29 '25Sale83.074,000332,28848,034Oct 01 08:14 PM
Darlene NociOfficerSep 29 '25Proposed Sale81.3012,000975,600Sep 29 04:08 PM
Alexandra BalcomOfficerSep 29 '25Proposed Sale81.3060,0004,878,000Sep 29 04:07 PM
Porter James RichardPresident and CEOSep 15 '25Option Exercise18.9327,000511,110276,062Sep 17 04:31 PM
Porter James RichardPresident and CEOSep 15 '25Sale79.0827,0002,135,055249,062Sep 17 04:31 PM
Pelish Henry E.Chief Scientific OfficerSep 10 '25Option Exercise26.943,725100,35469,688Sep 12 04:30 PM
Pelish Henry E.Chief Scientific OfficerSep 10 '25Sale78.833,725293,64265,963Sep 12 04:30 PM
HENRY E PELISHOfficerSep 10 '25Proposed Sale78.736,158484,819Sep 10 04:38 PM
Pelish Henry E.Chief Scientific OfficerAug 29 '25Option Exercise1.005,0074,98665,963Sep 03 04:30 PM
Noci DarleneChief Development OfficerAug 25 '25Option Exercise27.854,000111,40052,034Aug 27 04:30 PM
Noci DarleneChief Development OfficerAug 25 '25Sale74.624,000298,48948,034Aug 27 04:30 PM
Porter James RichardPresident and CEOAug 15 '25Option Exercise18.9327,000511,110276,062Aug 19 04:30 PM
Last Close
Feb 13  •  04:00PM ET
3.15
Dollar change
-0.06
Percentage change
-1.87
%
LRMR Larimar Therapeutics Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-1.93 Insider Own45.67% Shs Outstand85.59M Perf Week-6.53%
Market Cap269.61M Forward P/E- EPS next Y-1.82 Insider Trans0.00% Shs Float46.50M Perf Month-7.62%
Enterprise Value98.52M PEG- EPS next Q-0.49 Inst Own57.42% Short Float18.85% Perf Quarter-6.53%
Income-132.00M P/S- EPS this Y-47.86% Inst Trans11.83% Short Ratio7.02 Perf Half Y-26.06%
Sales0.00M P/B1.94 EPS next Y6.84% ROA-64.96% Short Interest8.77M Perf YTD-17.32%
Book/sh1.62 P/C1.54 EPS next 5Y-5.48% ROE-78.24% 52W High5.37 -41.34% Perf Year-3.67%
Cash/sh2.05 P/FCF- EPS past 3/5Y23.60% 50.78% ROIC-92.80% 52W Low1.61 95.65% Perf 3Y-50.08%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility5.77% 6.78% Perf 5Y-83.81%
Dividend TTM- EV/Sales- EPS Y/Y TTM-67.41% Oper. Margin- ATR (14)0.22 Perf 10Y-95.94%
Dividend Ex-Date- Quick Ratio4.06 Sales Y/Y TTM- Profit Margin- RSI (14)40.13 Recom1.09
Dividend Gr. 3/5Y- - Current Ratio4.06 EPS Q/Q-150.80% SMA20-7.28% Beta1.02 Target Price15.40
Payout- Debt/Eq0.03 Sales Q/Q- SMA50-11.47% Rel Volume0.35 Prev Close3.21
Employees65 LT Debt/Eq0.02 EarningsNov 05 BMO SMA200-9.11% Avg Volume1.25M Price3.15
IPOJun 19, 2014 Option/ShortYes / Yes EPS/Sales Surpr.-51.10% - Trades Volume442,386 Change-1.87%
Date Action Analyst Rating Change Price Target Change
Jan-29-25Initiated Truist Buy $18
Oct-16-24Initiated Oppenheimer Outperform $26
Oct-03-24Initiated Wedbush Outperform $22
Oct-02-24Initiated H.C. Wainwright Buy $15
Sep-04-24Initiated Robert W. Baird Outperform $16
Apr-03-24Initiated Leerink Partners Outperform $25
Nov-17-23Upgrade Citigroup Neutral → Buy $4.50
Oct-19-22Initiated Guggenheim Buy $12
Feb-15-22Downgrade William Blair Outperform → Mkt Perform
Feb-10-21Initiated JMP Securities Mkt Outperform
Dec-18-25 08:00AM
Nov-05-25 07:14AM
07:00AM
Oct-22-25 05:47PM
Oct-09-25 04:14PM
07:00AM Loading…
Sep-29-25 07:00AM
Sep-28-25 05:00PM
Aug-14-25 07:13AM
07:00AM
Jul-31-25 04:15PM
Jul-29-25 11:50PM
04:01PM
Jul-17-25 09:11AM
Jul-16-25 09:01AM
Jul-08-25 07:00AM
07:00AM Loading…
Jun-23-25 07:00AM
Jun-20-25 04:05PM
May-21-25 11:22AM
Apr-30-25 07:00AM
Apr-04-25 01:12PM
Mar-24-25 07:00AM
Mar-03-25 04:05PM
Jan-23-25 04:05PM
Dec-17-24 07:20AM
Dec-16-24 07:00AM
07:00AM
Nov-18-24 07:00AM
Oct-30-24 07:00AM
Sep-19-24 07:00AM
Aug-27-24 08:00AM
07:00AM Loading…
Aug-07-24 07:00AM
May-30-24 04:05PM
May-22-24 11:25AM
May-21-24 07:39AM
May-20-24 04:05PM
May-09-24 01:55PM
07:00AM
Mar-20-24 01:32PM
Mar-14-24 09:53PM
05:32PM
04:05PM
Mar-11-24 04:05PM
Mar-06-24 04:05PM
Feb-20-24 01:47PM
Feb-19-24 01:48PM
Feb-16-24 04:20PM
Feb-14-24 06:15AM
Feb-13-24 04:18PM
Feb-12-24 07:00AM
Nov-14-23 07:00AM
Nov-01-23 04:05PM
Oct-03-23 04:05PM
Aug-31-23 04:05PM
Aug-10-23 07:00AM
Aug-07-23 09:22AM
Jul-25-23 09:59AM
07:00AM
Jul-17-23 04:05PM
Jun-21-23 04:05PM
May-15-23 07:00AM
Mar-28-23 04:05PM
Mar-14-23 07:00AM
Feb-07-23 04:05PM
Nov-21-22 04:05PM
Nov-10-22 07:00AM
Nov-07-22 04:05PM
Oct-20-22 08:00AM
Oct-19-22 04:05PM
Sep-16-22 01:00PM
Sep-14-22 07:04AM
07:01AM
Aug-11-22 04:05PM
Jul-28-22 04:05PM
Jun-28-22 08:00AM
06:05AM
Jun-02-22 08:00AM
May-19-22 08:00AM
May-12-22 07:00AM
Apr-29-22 06:27AM
Apr-13-22 10:40AM
Mar-25-22 07:00AM
Feb-16-22 11:57AM
Feb-14-22 04:01PM
Jan-19-22 06:53AM
Nov-22-21 07:00AM
Nov-20-21 08:40AM
Nov-15-21 07:00AM
Nov-12-21 07:00AM
Sep-16-21 08:00AM
Sep-02-21 04:01PM
Aug-22-21 10:12AM
Aug-19-21 07:00AM
Aug-12-21 07:00AM
Aug-09-21 08:48AM
Jul-23-21 12:00PM
Jul-08-21 04:01PM
Jun-11-21 07:00AM
Jun-05-21 07:55PM
Jun-02-21 10:56PM
Jun-01-21 04:55AM
Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Flynn James EDirectorJul 31 '25Buy3.209,375,00030,000,0009,538,945Aug 04 06:28 PM
Last Close
Feb 13  •  04:00PM ET
8.85
Dollar change
+0.04
Percentage change
0.45
%
SPRY ARS Pharmaceuticals Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-0.81 Insider Own38.43% Shs Outstand98.84M Perf Week-11.76%
Market Cap874.82M Forward P/E- EPS next Y-1.38 Insider Trans-0.79% Shs Float60.86M Perf Month-24.94%
Enterprise Value684.37M PEG- EPS next Q-0.43 Inst Own70.09% Short Float35.16% Perf Quarter-1.06%
Income-80.04M P/S6.13 EPS this Y-2247.92% Inst Trans15.39% Short Ratio12.12 Perf Half Y-38.84%
Sales142.77M P/B5.92 EPS next Y19.69% ROA-27.11% Short Interest21.40M Perf YTD-24.03%
Book/sh1.49 P/C3.04 EPS next 5Y- ROE-45.92% 52W High18.90 -53.17% Perf Year-25.76%
Cash/sh2.92 P/FCF- EPS past 3/5Y- - ROIC-32.69% 52W Low6.66 32.88% Perf 3Y13.46%
Dividend Est.- EV/EBITDA- Sales past 3/5Y152.98% - Gross Margin89.29% Volatility6.47% 5.77% Perf 5Y-80.23%
Dividend TTM- EV/Sales4.79 EPS Y/Y TTM-59.70% Oper. Margin-63.59% ATR (14)0.62 Perf 10Y-
Dividend Ex-Date- Quick Ratio6.51 Sales Y/Y TTM5459.66% Profit Margin-56.06% RSI (14)35.19 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio6.66 EPS Q/Q-162.66% SMA20-11.83% Beta0.79 Target Price28.33
Payout0.00% Debt/Eq0.66 Sales Q/Q1471.62% SMA50-16.23% Rel Volume1.21 Prev Close8.81
Employees160 LT Debt/Eq0.66 EarningsNov 10 BMO SMA200-28.44% Avg Volume1.77M Price8.85
IPODec 04, 2020 Option/ShortYes / Yes EPS/Sales Surpr.-14.59% 13.35% Trades Volume2,133,139 Change0.45%
Date Action Analyst Rating Change Price Target Change
Nov-04-25Resumed Roth Capital Buy $30
Sep-04-25Initiated Roth Capital Buy $40
Mar-07-25Initiated Scotiabank Sector Outperform $30
Feb-10-25Initiated Oppenheimer Outperform $40
Aug-20-24Initiated Cantor Fitzgerald Overweight
Aug-13-24Upgrade Raymond James Outperform → Strong Buy $18 → $22
Aug-12-24Reiterated Leerink Partners Outperform $19 → $20
Jul-25-24Initiated Raymond James Outperform $18
Mar-05-24Upgrade Leerink Partners Market Perform → Outperform $6 → $18
Feb-20-24Upgrade William Blair Mkt Perform → Outperform
Feb-10-26 08:00AM
Feb-02-26 01:12PM
Jan-21-26 08:00AM
Jan-09-26 12:32PM
11:28AM
03:16AM Loading…
03:16AM
Dec-30-25 08:10AM
Dec-29-25 08:00AM
Nov-26-25 08:00AM
Nov-10-25 04:01PM
07:05AM
06:00AM
Nov-07-25 07:19AM
Nov-06-25 09:10AM
Nov-05-25 09:15AM
09:35AM Loading…
Nov-04-25 09:35AM
08:00AM
Nov-03-25 02:23PM
08:00AM
07:45AM
Oct-08-25 08:00AM
Sep-29-25 04:05PM
Sep-19-25 08:00AM
Sep-17-25 11:44AM
Sep-09-25 08:11AM
Sep-08-25 08:00AM
Sep-04-25 02:54PM
Aug-28-25 08:00AM
Aug-13-25 08:15AM
07:00AM
05:26AM Loading…
05:26AM
Aug-12-25 09:24AM
Aug-11-25 06:55PM
Aug-08-25 01:56PM
Aug-04-25 08:00AM
Jul-31-25 05:35PM
08:50AM
Jul-30-25 10:00AM
Jul-29-25 10:00AM
Jul-18-25 12:27PM
09:25AM
Jul-15-25 12:00PM
09:55AM
08:50AM
Jun-15-25 05:26AM
Jun-11-25 09:02PM
May-27-25 08:00AM
May-15-25 03:12AM
May-14-25 10:44PM
08:15AM
07:00AM
May-13-25 09:28AM
May-08-25 05:06AM
May-05-25 08:00AM
May-04-25 04:32PM
May-02-25 08:00AM
08:00AM
Apr-30-25 06:51AM
Apr-05-25 05:31PM
Mar-23-25 07:18AM
Mar-21-25 12:16PM
12:03PM
03:03AM
12:40AM
Mar-20-25 04:04PM
03:31PM
01:29PM
01:28PM
08:25AM
07:00AM
Mar-06-25 05:27AM
Mar-03-25 04:35PM
Feb-20-25 07:02PM
Feb-18-25 08:00AM
Feb-05-25 08:00AM
Jan-21-25 08:00AM
Jan-13-25 04:15PM
08:00AM
Jan-07-25 08:15AM
06:43AM
Jan-06-25 08:00AM
08:00AM
Dec-19-24 05:25PM
Dec-18-24 08:00AM
Dec-12-24 02:32PM
Dec-04-24 08:00AM
Nov-14-24 02:08AM
Nov-13-24 07:40AM
06:30AM
Nov-12-24 07:06AM
Nov-11-24 04:02PM
11:01AM
07:41AM
07:00AM
Nov-09-24 05:30PM
Nov-06-24 09:55AM
08:00AM
Oct-24-24 08:30AM
Oct-14-24 09:55AM
Sep-30-24 10:33AM
ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dorsey BrianChief Operating OfficerNov 13 '25Option Exercise0.6421,82813,97032,617Nov 14 06:43 PM
Dorsey BrianChief Operating OfficerNov 13 '25Sale8.7121,828190,05010,789Nov 14 06:43 PM
Chakma JustinChief Business OfficerNov 12 '25Option Exercise0.8430,00025,200166,380Nov 14 06:42 PM
Chakma JustinChief Business OfficerNov 12 '25Sale8.87166,3801,476,1470Nov 14 06:42 PM
BRIAN T DORSEYOfficerNov 13 '25Proposed Sale8.7121,828190,050Nov 13 04:08 PM
JUSTIN CHAKMAOfficerNov 12 '25Proposed Sale8.9130,000267,357Nov 12 05:26 PM
Chakma JustinOfficerNov 12 '25Proposed Sale8.87138,3801,227,420Nov 12 10:56 AM
Lowenthal Richard EPRESIDENT AND CEOAug 21 '25Sale14.4950,000724,3451,196,494Aug 22 04:30 PM
Scott Kathleen D.Chief Financial OfficerAug 21 '25Option Exercise1.5012,50018,75022,542Aug 22 04:30 PM
Scott Kathleen D.Chief Financial OfficerAug 21 '25Sale15.0012,500187,50010,042Aug 22 04:30 PM
Tanimoto SarinaCHIEF MEDICAL OFFICERAug 20 '25Sale14.0937,656530,6261,247,447Aug 21 05:36 PM
Tanimoto SarinaCHIEF MEDICAL OFFICERAug 19 '25Sale14.0312,344173,1301,285,103Aug 21 05:36 PM
KATHLEEN D SCOTTOfficerAug 21 '25Proposed Sale15.0012,500187,500Aug 21 04:18 PM
Lowenthal Richard EOfficerAug 21 '25Proposed Sale14.15150,0002,123,000Aug 21 11:20 AM
Tanimoto SarinaOfficerAug 19 '25Proposed Sale14.00150,0002,100,000Aug 19 10:22 AM
Karas EricChief Commercial OfficerJul 01 '25Option Exercise1.5015,00022,50025,315Jul 03 04:21 PM
Karas EricChief Commercial OfficerJul 01 '25Sale16.9915,000254,86010,315Jul 03 04:21 PM
Flynn James E10% OwnerJun 27 '25Sale18.46740,14913,663,1514,887,254Jul 01 04:42 PM
ERIC KARASOfficerJul 01 '25Proposed Sale16.9915,000254,859Jul 01 04:20 PM
Karas EricChief Commercial OfficerJun 18 '25Option Exercise1.5015,00022,50022,696Jun 20 06:38 PM
Karas EricChief Commercial OfficerJun 18 '25Sale16.0015,000240,0007,696Jun 20 06:38 PM
ERIC KARASOfficerJun 18 '25Proposed Sale16.0015,000240,000Jun 18 04:51 PM
Fitzpatrick Alexander AChief Legal OfficerMay 20 '25Option Exercise5.58100,000558,000192,582May 22 05:00 PM
Fitzpatrick Alexander AChief Legal OfficerMay 20 '25Sale14.10102,9691,451,51389,613May 22 05:00 PM
SAUNDERS BRENT LDirectorMay 20 '25Option Exercise1.01120,000121,200120,000May 22 05:00 PM
SAUNDERS BRENT LDirectorMay 20 '25Sale14.25120,0001,710,0240May 22 05:00 PM
Scott Kathleen D.Chief Financial OfficerMay 20 '25Option Exercise1.5050,00075,00057,424May 22 05:00 PM
Scott Kathleen D.Chief Financial OfficerMay 20 '25Sale14.1050,000705,1657,424May 22 05:00 PM
Scott Kathleen D.OfficerMay 20 '25Proposed Sale14.1050,000705,000May 20 05:24 PM
Fitzpatrick Alexander AOfficerMay 20 '25Proposed Sale14.02102,9691,443,894May 20 04:50 PM
SAUNDERS BRENT LDirectorMay 20 '25Proposed Sale14.25120,0001,710,000May 20 04:48 PM
Shawver LauraDirectorApr 07 '25Option Exercise4.8550,002242,510260,348Apr 08 04:45 PM
Shawver LauraDirectorApr 07 '25Sale12.3050,002615,075210,346Apr 08 04:45 PM
Shawver LauraDirectorApr 07 '25Proposed Sale12.3050,002615,051Apr 07 02:26 PM
Karas EricChief Commercial OfficerMar 20 '25Option Exercise1.5010,00015,00017,696Mar 21 06:30 PM
Karas EricChief Commercial OfficerMar 20 '25Sale14.0010,000140,0007,696Mar 21 06:30 PM
ERIC KARASOfficerMar 20 '25Proposed Sale14.0010,000140,000Mar 20 04:03 PM
Shawver LauraDirectorMar 06 '25Option Exercise4.8549,600240,560259,946Mar 07 05:12 PM
Shawver LauraDirectorMar 05 '25Option Exercise4.854001,940210,746Mar 07 05:12 PM
Shawver LauraDirectorMar 06 '25Sale11.2149,600556,046210,346Mar 07 05:12 PM
Shawver LauraDirectorMar 05 '25Sale11.004004,400210,346Mar 07 05:12 PM
Shawver LauraDirectorMar 05 '25Proposed Sale11.0050,000550,000Mar 05 05:19 PM
Last Close
Feb 13  •  04:00PM ET
14.21
Dollar change
+0.15
Percentage change
1.07
%
BCAX Bicara Therapeutics Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-2.23 Insider Own41.59% Shs Outstand54.61M Perf Week-7.49%
Market Cap778.42M Forward P/E- EPS next Y-3.03 Insider Trans-1.33% Shs Float32.00M Perf Month-21.14%
Enterprise Value490.23M PEG- EPS next Q-0.67 Inst Own70.93% Short Float27.81% Perf Quarter-4.69%
Income-121.52M P/S- EPS this Y37.91% Inst Trans6.23% Short Ratio16.33 Perf Half Y24.54%
Sales0.00M P/B1.93 EPS next Y-20.62% ROA-25.61% Short Interest8.90M Perf YTD-15.57%
Book/sh7.38 P/C2.68 EPS next 5Y8.12% ROE-26.64% 52W High19.71 -27.90% Perf Year8.31%
Cash/sh5.30 P/FCF- EPS past 3/5Y-34.00% - ROIC-30.10% 52W Low7.80 82.18% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility6.34% 6.41% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM-103.95% Oper. Margin- ATR (14)1.01 Perf 10Y-
Dividend Ex-Date- Quick Ratio14.14 Sales Y/Y TTM- Profit Margin- RSI (14)32.61 Recom1.46
Dividend Gr. 3/5Y- - Current Ratio14.14 EPS Q/Q-107.22% SMA20-11.71% Beta-0.50 Target Price29.27
Payout- Debt/Eq0.00 Sales Q/Q- SMA50-16.43% Rel Volume0.46 Prev Close14.06
Employees55 LT Debt/Eq0.00 EarningsNov 10 BMO SMA2001.75% Avg Volume545.04K Price14.21
IPOSep 13, 2024 Option/ShortYes / Yes EPS/Sales Surpr.-23.82% - Trades Volume250,324 Change1.07%
Date Action Analyst Rating Change Price Target Change
Jan-29-26Initiated Citizens JMP Mkt Perform $31
Jan-08-26Initiated BTIG Research Buy $28
Dec-18-25Initiated Mizuho Neutral $18
Aug-19-25Initiated Piper Sandler Overweight $36
May-23-25Upgrade Wells Fargo Underweight → Equal Weight $8
Apr-17-25Initiated Wells Fargo Underweight $8
Feb-06-25Initiated Wedbush Outperform $31
Dec-06-24Initiated H.C. Wainwright Buy $42
Nov-05-24Initiated Rodman & Renshaw Buy $48
Oct-08-24Initiated TD Cowen Buy
Feb-05-26 08:30AM
Jan-13-26 01:08AM
Jan-12-26 08:00AM
Dec-15-25 08:00AM
Dec-06-25 08:00AM
07:00AM Loading…
Dec-01-25 07:00AM
Nov-10-25 07:30AM
Oct-27-25 08:30AM
Oct-13-25 07:30AM
Aug-27-25 04:01PM
Aug-14-25 09:55AM
Aug-12-25 07:30AM
Jun-11-25 04:05PM
Jun-03-25 04:01PM
Jun-01-25 01:12PM
06:54AM Loading…
May-29-25 06:54AM
May-27-25 01:59PM
May-26-25 09:14AM
May-23-25 10:15AM
May-22-25 05:00PM
May-13-25 07:30AM
Apr-28-25 04:01PM
Apr-23-25 10:00AM
Apr-19-25 06:22AM
Mar-27-25 07:30AM
Mar-25-25 04:45PM
Feb-24-25 04:01PM
Feb-11-25 04:01PM
Jan-27-25 08:00AM
Jan-08-25 10:16AM
07:30AM Loading…
Nov-12-24 07:30AM
Nov-11-24 04:01PM
Oct-14-24 06:45AM
Oct-08-24 10:44AM
Sep-23-24 07:05PM
Sep-19-24 01:13AM
Sep-18-24 03:01PM
Sep-17-24 09:13AM
Sep-16-24 04:01PM
Sep-13-24 04:09PM
12:19AM
Sep-12-24 09:15PM
07:02PM
Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company's bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cohlhepp RyanPresident and COOJan 22 '26Sale18.103,82869,296210,164Jan 26 04:34 PM
Hyep IvanChief Financial OfficerJan 22 '26Option Exercise3.791,8827,132147,237Jan 26 04:33 PM
Hyep IvanChief Financial OfficerJan 22 '26Sale18.151,88234,162145,355Jan 26 04:33 PM
Cohlhepp RyanOfficerJan 22 '26Proposed Sale16.973,82864,961Jan 22 04:07 PM
Hyep IvanOfficerJan 22 '26Proposed Sale18.151,88234,158Jan 22 04:03 PM
Cohlhepp RyanPresident and COOJan 15 '26Sale18.021492,685213,992Jan 20 04:52 PM
Cohlhepp RyanOfficerJan 15 '26Proposed Sale18.021492,685Jan 15 04:03 PM
Cohlhepp RyanPresident and COODec 26 '25Option Exercise4.4425,000110,922214,141Dec 29 05:18 PM
Raben DavidChief Medical OfficerDec 26 '25Option Exercise3.7919,78974,99655,286Dec 29 05:10 PM
Hyep IvanChief Financial OfficerDec 22 '25Option Exercise3.799,20034,866154,555Dec 23 04:02 PM
Hyep IvanChief Financial OfficerDec 22 '25Sale18.319,200168,492145,355Dec 23 04:02 PM
Hyep IvanOfficerDec 22 '25Proposed Sale17.879,200164,404Dec 22 04:08 PM
Mazumdar ClaireChief Executive OfficerDec 16 '25Option Exercise5.4529,500160,884339,392Dec 18 06:02 PM
Cohlhepp RyanPresident and COODec 15 '25Option Exercise3.798,00030,318201,641Dec 16 04:52 PM
Cohlhepp RyanPresident and COODec 15 '25Sale18.6812,500233,548189,141Dec 16 04:52 PM
Cohlhepp RyanOfficerDec 15 '25Proposed Sale18.7012,500233,750Dec 15 04:04 PM
Hyep IvanChief Financial OfficerNov 24 '25Option Exercise3.7917,79567,439163,150Nov 25 06:42 PM
Hyep IvanChief Financial OfficerNov 21 '25Option Exercise3.796052,293145,960Nov 25 06:42 PM
Hyep IvanChief Financial OfficerNov 24 '25Sale18.5517,795330,094145,355Nov 25 06:42 PM
Hyep IvanChief Financial OfficerNov 21 '25Sale18.1560510,981145,355Nov 25 06:42 PM
Cohlhepp RyanPresident and COONov 21 '25Option Exercise3.798,00030,318206,141Nov 25 06:41 PM
Cohlhepp RyanPresident and COONov 21 '25Sale18.0512,500225,588193,641Nov 25 06:41 PM
Mazumdar ClaireChief Executive OfficerNov 24 '25Option Exercise3.7941,163156,000351,055Nov 25 06:40 PM
Mazumdar ClaireChief Executive OfficerNov 24 '25Sale18.8641,163776,429309,892Nov 25 06:40 PM
Raben DavidChief Medical OfficerNov 24 '25Option Exercise3.795,50020,84440,997Nov 25 06:39 PM
Raben DavidChief Medical OfficerNov 25 '25Option Exercise3.795,50020,84440,091Nov 25 06:39 PM
Raben DavidChief Medical OfficerNov 25 '25Sale18.845,500103,63335,497Nov 25 06:39 PM
Raben DavidChief Medical OfficerNov 24 '25Sale18.455,500101,47535,497Nov 25 06:39 PM
Raben DavidOfficerNov 25 '25Proposed Sale18.845,500103,633Nov 25 04:29 PM
Mazumdar ClaireOfficerNov 24 '25Proposed Sale18.8641,163776,429Nov 24 04:24 PM
Hyep IvanOfficerNov 24 '25Proposed Sale18.5517,795330,094Nov 24 04:10 PM
Raben DavidOfficerNov 24 '25Proposed Sale18.455,500101,475Nov 24 04:09 PM
Hyep IvanOfficerNov 21 '25Proposed Sale18.1560510,981Nov 21 04:33 PM
Cohlhepp RyanOfficerNov 21 '25Proposed Sale18.0512,500225,588Nov 21 04:32 PM
Cohlhepp RyanPresident and COOOct 15 '25Option Exercise3.798,00030,318210,641Oct 16 04:41 PM
Cohlhepp RyanPresident and COOOct 15 '25Sale18.1612,500226,942198,141Oct 16 04:41 PM
Mazumdar ClaireOfficerOct 16 '25Proposed Sale18.8324,103453,761Oct 16 04:13 PM
Mazumdar ClaireChief Executive OfficerOct 15 '25Option Exercise3.7913,28950,363323,181Oct 15 06:00 PM
Mazumdar ClaireChief Executive OfficerOct 13 '25Option Exercise3.7911,44543,374321,337Oct 15 06:00 PM
Mazumdar ClaireChief Executive OfficerOct 15 '25Sale18.8413,289250,391309,892Oct 15 06:00 PM
Mazumdar ClaireChief Executive OfficerOct 13 '25Sale18.9211,445216,545309,892Oct 15 06:00 PM
Cohlhepp RyanOfficerOct 15 '25Proposed Sale18.1312,500226,601Oct 15 04:20 PM
Mazumdar ClaireOfficerOct 15 '25Proposed Sale18.8413,289250,391Oct 15 04:18 PM
Mazumdar ClaireOfficerOct 13 '25Proposed Sale18.9211,445216,545Oct 14 09:05 AM
Raben DavidChief Medical OfficerOct 09 '25Option Exercise3.7922,00083,37657,497Oct 10 05:23 PM
Raben DavidChief Medical OfficerOct 09 '25Sale18.4522,000405,90035,497Oct 10 05:23 PM
Hyep IvanChief Financial OfficerOct 09 '25Option Exercise3.796,41524,312151,770Oct 10 05:22 PM
Hyep IvanChief Financial OfficerOct 09 '25Sale18.236,415116,931145,355Oct 10 05:22 PM
Hyep IvanOfficerOct 09 '25Proposed Sale17.896,415114,764Oct 09 04:31 PM
Raben DavidOfficerOct 09 '25Proposed Sale18.4522,000405,900Oct 09 04:08 PM
Hyep IvanChief Financial OfficerOct 07 '25Option Exercise3.7918,24469,141163,599Oct 08 05:33 PM
Hyep IvanChief Financial OfficerOct 06 '25Option Exercise3.796,51424,687151,869Oct 08 05:33 PM
Hyep IvanChief Financial OfficerOct 08 '25Option Exercise3.795,62721,325150,982Oct 08 05:33 PM
Hyep IvanChief Financial OfficerOct 07 '25Sale18.2218,244332,386145,355Oct 08 05:33 PM
Hyep IvanChief Financial OfficerOct 06 '25Sale18.176,514118,356145,355Oct 08 05:33 PM
Hyep IvanChief Financial OfficerOct 08 '25Sale18.215,627102,456145,355Oct 08 05:33 PM
Cohlhepp RyanPresident and COOOct 06 '25Option Exercise3.7924,00090,955245,141Oct 08 05:33 PM
Cohlhepp RyanPresident and COOOct 07 '25Option Exercise3.798,00030,318213,541Oct 08 05:33 PM
Cohlhepp RyanPresident and COOOct 06 '25Sale18.0639,600714,998205,541Oct 08 05:33 PM
Cohlhepp RyanPresident and COOOct 07 '25Sale18.0610,900196,844202,641Oct 08 05:33 PM
Hyep IvanOfficerOct 08 '25Proposed Sale18.175,627102,242Oct 08 04:04 PM
Hyep IvanOfficerOct 07 '25Proposed Sale18.0018,244328,392Oct 07 04:20 PM
Cohlhepp RyanOfficerOct 07 '25Proposed Sale18.0010,900196,200Oct 07 04:07 PM
Cohlhepp RyanOfficerOct 06 '25Proposed Sale18.0639,600714,997Oct 06 04:36 PM
Hyep IvanOfficerOct 06 '25Proposed Sale17.046,514110,998Oct 06 04:07 PM
Meisner LaraChief Legal OfficerSep 29 '25Option Exercise9.2433,807312,49533,807Oct 01 04:57 PM
Meisner LaraChief Legal OfficerSep 29 '25Sale14.7533,807498,6530Oct 01 04:57 PM
LARA MEISNEROfficerSep 29 '25Proposed Sale11.7133,807395,880Sep 29 04:38 PM
Meisner LaraChief Legal OfficerSep 15 '25Option Exercise5.4515,82986,26815,829Sep 17 05:01 PM
Meisner LaraChief Legal OfficerSep 15 '25Sale11.4915,829181,8750Sep 17 05:01 PM
Meisner LaraChief Legal OfficerJun 16 '25Option Exercise5.4515,82986,26815,829Jun 18 05:12 PM
Meisner LaraChief Legal OfficerJun 16 '25Sale10.4315,829165,0960Jun 18 05:12 PM
LARA S. MEISNEROfficerJun 16 '25Proposed Sale10.8431,658343,173Jun 16 04:29 PM
Meisner LaraChief Legal OfficerMar 14 '25Option Exercise5.4579,146431,34679,145Mar 18 06:35 PM
Meisner LaraChief Legal OfficerMar 14 '25Sale12.9079,1461,021,2110Mar 18 06:35 PM
LARA S. MEISNEROfficerMar 14 '25Proposed Sale13.3579,1461,056,599Mar 14 04:21 PM
Last Close
Feb 13  •  04:00PM ET
10.20
Dollar change
+0.11
Percentage change
1.09
%
AHCO AdaptHealth Corp daily Stock Chart
IndexRUT P/E18.71 EPS (ttm)0.55 Insider Own34.89% Shs Outstand135.42M Perf Week-4.23%
Market Cap1.38B Forward P/E10.27 EPS next Y0.99 Insider Trans-0.03% Shs Float88.17M Perf Month-3.23%
Enterprise Value3.21B PEG2.01 EPS next Q0.35 Inst Own79.25% Short Float8.85% Perf Quarter9.44%
Income74.69M P/S0.42 EPS this Y-35.08% Inst Trans0.41% Short Ratio7.82 Perf Half Y7.48%
Sales3.26B P/B0.85 EPS next Y44.01% ROA1.69% Short Interest7.80M Perf YTD2.41%
Book/sh11.94 P/C17.19 EPS next 5Y5.10% ROE4.77% 52W High11.63 -12.30% Perf Year14.22%
Cash/sh0.59 P/FCF6.48 EPS past 3/5Y-19.58% - ROIC2.16% 52W Low7.11 43.56% Perf 3Y-51.82%
Dividend Est.- EV/EBITDA4.85 Sales past 3/5Y9.93% 43.84% Gross Margin18.05% Volatility3.86% 3.99% Perf 5Y-68.99%
Dividend TTM- EV/Sales0.99 EPS Y/Y TTM133.76% Oper. Margin7.46% ATR (14)0.40 Perf 10Y-
Dividend Ex-Date- Quick Ratio0.86 Sales Y/Y TTM-0.23% Profit Margin2.29% RSI (14)48.65 Recom1.62
Dividend Gr. 3/5Y- - Current Ratio1.08 EPS Q/Q6.72% SMA20-0.63% Beta1.74 Target Price13.38
Payout0.00% Debt/Eq1.18 Sales Q/Q1.79% SMA500.15% Rel Volume0.63 Prev Close10.09
Employees10500 LT Debt/Eq1.14 EarningsFeb 24 BMO SMA2008.26% Avg Volume997.97K Price10.20
IPOMay 24, 2018 Option/ShortYes / Yes EPS/Sales Surpr.-1.66% 2.63% Trades Volume628,373 Change1.09%
Date Action Analyst Rating Change Price Target Change
Jan-08-24Downgrade Jefferies Buy → Hold $14.50 → $8
Nov-08-23Downgrade BofA Securities Neutral → Underperform $9.50 → $6.50
May-10-23Downgrade Stifel Buy → Hold $18 → $11
May-10-23Downgrade Deutsche Bank Buy → Hold $28 → $11.30
May-09-23Downgrade BofA Securities Buy → Neutral $21 → $12
Sep-27-21Initiated SVB Leerink Outperform $30
Jul-14-21Upgrade Robert W. Baird Neutral → Outperform $30 → $36
Apr-13-21Downgrade Robert W. Baird Outperform → Neutral
Mar-18-21Initiated Truist Buy
Jan-26-21Initiated BofA Securities Buy $46
Feb-04-26 07:30AM
Feb-03-26 04:05PM
Jan-27-26 09:20AM
Jan-06-26 10:37PM
Dec-22-25 11:02PM
03:30PM Loading…
Dec-05-25 03:30PM
Dec-04-25 09:00AM
Nov-26-25 08:30AM
Nov-17-25 07:59PM
Nov-04-25 04:08PM
09:05AM
07:32AM
07:00AM
Nov-03-25 07:43AM
Nov-02-25 10:03PM
04:05PM Loading…
Oct-30-25 04:05PM
Oct-27-25 07:00AM
Oct-13-25 04:05PM
Oct-03-25 12:01AM
Sep-22-25 04:05PM
07:22AM
Sep-10-25 11:33PM
Aug-26-25 08:38AM
Aug-22-25 03:45PM
Aug-13-25 12:21AM
12:10AM
Aug-05-25 03:50PM
08:15AM
07:49AM
07:01AM
07:00AM Loading…
07:00AM
Aug-04-25 04:05PM
09:43AM
Aug-03-25 11:14PM
Jul-31-25 10:00AM
Jul-29-25 10:00AM
12:01AM
Jul-16-25 09:39AM
Jul-15-25 04:05PM
Jul-08-25 05:00PM
Jun-30-25 04:05PM
Jun-26-25 06:02PM
May-19-25 08:56AM
May-13-25 04:01PM
May-07-25 09:00PM
May-06-25 08:15AM
07:00AM
May-05-25 09:51AM
May-02-25 01:22PM
01:21PM
May-01-25 11:46AM
11:34AM
11:32AM
10:40AM
09:13AM
Apr-30-25 11:25AM
Apr-29-25 12:00PM
11:40AM
Apr-28-25 09:04AM
Apr-25-25 05:09AM
Apr-21-25 04:05PM
12:48PM
Apr-16-25 08:45AM
Apr-10-25 08:31AM
Apr-08-25 08:39AM
Mar-30-25 10:00AM
Mar-12-25 05:02AM
Mar-06-25 04:05PM
Mar-03-25 09:40AM
Feb-27-25 10:10AM
Feb-26-25 08:14AM
02:07AM
02:02AM
Feb-25-25 01:59PM
08:40AM
07:31AM
07:00AM
01:39AM
Feb-24-25 08:05AM
Feb-17-25 09:35AM
Feb-14-25 04:03AM
04:03AM
04:01AM
Feb-13-25 09:40AM
Feb-11-25 04:02AM
Feb-04-25 04:05PM
Jan-28-25 09:40AM
Dec-03-24 08:00AM
Nov-26-24 04:05PM
08:34AM
Nov-12-24 04:05PM
Nov-06-24 02:11AM
Nov-05-24 06:42PM
08:40AM
07:26AM
Oct-24-24 09:40AM
09:40AM
Oct-22-24 10:01AM
Oct-17-24 08:00AM
Oct-16-24 08:30AM
AdaptHealth Corp. engages in the provision of home healthcare equipment, supplies and related services. It focuses on sleep therapy equipment to individuals suffering from obstructive sleep apnea (OSA), home medical equipment to patients discharged from acute care and other facilities, oxygen and related chronic therapy services in the home, and HME medical devices and supplies on behalf of chronically ill patients with diabetes care, wound care, urological, ostomy, and nutritional supply needs. The company was founded in 2012 and is headquartered in Conshohocken, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Williams David Solomon IIIDirectorDec 04 '25Sale9.435,00047,15045,045Dec 05 05:35 PM
DAVID S WILLIAMSDirectorDec 04 '25Proposed Sale9.435,00047,150Dec 04 04:21 PM
Williams David Solomon IIIDirectorAug 22 '25Sale9.738,20079,78650,045Aug 22 07:33 PM